Zetagen Therapeutics Secures 9.79 Million USD Series B Funding Raise for Advancement of ZetaMet™ and ZetaMAST™ for Treatment of Metastatic Bone and Soft Tissue Lesions
/
DateAug 11 2023
ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. ZetaMet™ is presently in Phase 2a clinical trials for... Read More →